Hospital-Acquired Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Observational Study
Open Access
- 16 June 2023
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 11 (6) , 1595
Abstract
Worldwide, hospital-acquired infections (HAIs) are continuously rising within healthcare settings, leading to high mortality and morbidity rates. Many hospitals have reported the spread of carbapenemases globally, specifically within the E. coli and K. pneumoniae species. This study was aimed at analyzing the state of hospital-acquired, carbapenem-resistant E. coli and K. pneumoniae in the United Kingdom between 2009 and 2021. Moreover, the study analyzed the most efficacious approaches to patient management for controlling the carbapenem-resistant Enterobacteriaceae (CRE) spread. Initially, 1094 articles were identified as relevant for screening, and among them, 49 papers were eligible for full-text screening, with a total of 14 articles meeting the inclusion criteria. The information was recorded from published articles through PubMed, the Web of Science, Scopus, Science Direct, and the Cochrane library and was used to search for hospital-acquired carbapenem-resistant E. coli and K pneumoniae in the UK between 2009 and 2021, in order to evaluate the spread of CRE in hospitals. The total number of carbapenem-resistant E. coli was 1083 and this was 2053 for carbapenem-resistant K. pneumoniae in more than 63 UK hospitals. KPC was the dominant carbapenemase produced by K. pneumoniae. The results showed that the treatment options considered depended on the type of carbapenemase produced; K. pneumoniae showed more resistance to a treatment options, i.e., Colistin, than the other carbapenemase. The current state of the UK is at minimal risk for a CRE outbreak; however, appropriate treatment and infection control measures are highly required to prevent this CRE spread at the regional and global levels. The present study findings have an important message for physicians, healthcare workers, and policymakers about hospital-acquired carbapenem-resistant E. coli and K. pneumoniae spread and approaches to patient management.Keywords
Funding Information
- Deputyship for Research & Innovation, Ministry of Education, Saudi Arabia (IFKSUOR3-4-2)
This publication has 42 references indexed in Scilit:
- Molecular surveillance and clinical outcomes of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae infectionsJournal of Microbiology, Immunology and Infection, 2014
- An overview of carbapenem-resistant Klebsiella pneumoniaeReviews and Research in Medical Microbiology, 2014
- Emergence of carbapenem-resistant Enterobacteriaceae in a UK paediatric hospitalJournal of Hospital Infection, 2013
- The multiple roles of antibiotics and antibiotic resistance in natureFrontiers in Microbiology, 2013
- Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UKJournal of Antimicrobial Chemotherapy, 2012
- OXA-48-like carbapenemases: the phantom menaceJournal of Antimicrobial Chemotherapy, 2012
- Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to ActionAntimicrobial Resistance & Infection Control, 2012
- Antimicrobial Resistance: A Global Public Health ThreatJournal of the Eritrean Medical Association, 2010
- Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenemDiagnostic Microbiology and Infectious Disease, 2009
- Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United KingdomJournal of Antimicrobial Chemotherapy, 2008